Pfizer Inc

More Details of Pfizer Inc Company

Company Info

Company codePFE

Company namePfizer Inc

IPO dateJan 17, 1944

Founded at1942

CEODr. Albert Bourla, Ph.D.

Number of employees81000

Security typeOrdinary Share

Fiscal year-endJan 17

Address66 Hudson Boulevard East

CityNEW YORK

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code10001-2192

Phone12127332323

Websitehttps://www.pfizer.com/

Company codePFE

IPO dateJan 17, 1944

Founded at1942

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

367.99K

+10.69%

Mr. Douglas M. Lankler

Executive Vice President, General Counsel

161.03K

+8.26%

Dr. Mikael G. Dolsten, M.D., Ph.D.

Chief Scientific Officer, President - Pfizer Research and Development

128.13K

-26.53%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.93K

+8.23%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-0.78%

Mr. Ronald E. Blaylock

Independent Director

32.45K

+149.66%

Ms. Lidia L. Fonseca, Ph.D.

Executive Vice President, Chief Digital and Technology Officer

30.96K

--

Ms. Payal Sahni

Executive Vice President, Chief People Experience Officer

24.85K

+6.62%

Dr. Scott Gottlieb, M.D.

Independent Director

10.00K

+11.11%

Mr. James Clifton (Jim) Smith

Independent Director

3.54K

--

Name

Name/Position

Position

Shareholding

Change

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

367.99K

+10.69%

Mr. Douglas M. Lankler

Executive Vice President, General Counsel

161.03K

+8.26%

Dr. Mikael G. Dolsten, M.D., Ph.D.

Chief Scientific Officer, President - Pfizer Research and Development

128.13K

-26.53%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.93K

+8.23%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-0.78%

Mr. Ronald E. Blaylock

Independent Director

32.45K

+149.66%

Revenue Breakdown

Currency: USDUpdate time: Wed, Mar 5

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Eliquis alliance revenues and direct sales

7.36B

11.57%

Prevnar family

6.41B

10.07%

Paxlovid

5.71B

8.98%

Vyndaqel family

5.45B

8.56%

Comirnaty

5.35B

8.41%

Other

33.33B

52.38%

By RegionUSD

Name

Revenue

Proportion

United States

38.69B

60.80%

Developed Markets

16.05B

25.23%

Emerging Markets

8.87B

13.95%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Eliquis alliance revenues and direct sales

7.36B

11.57%

Prevnar family

6.41B

10.07%

Paxlovid

5.71B

8.98%

Vyndaqel family

5.45B

8.56%

Comirnaty

5.35B

8.41%

Other

33.33B

52.38%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.10%

State Street Global Advisors (US)

5.12%

BlackRock Institutional Trust Company, N.A.

4.93%

Charles Schwab Investment Management, Inc.

2.74%

Wellington Management Company, LLP

2.47%

Other

75.62%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.10%

State Street Global Advisors (US)

5.12%

BlackRock Institutional Trust Company, N.A.

4.93%

Charles Schwab Investment Management, Inc.

2.74%

Wellington Management Company, LLP

2.47%

Other

75.62%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

30.95%

Investment Advisor

24.86%

Research Firm

2.99%

Pension Fund

2.13%

Bank and Trust

1.86%

Hedge Fund

1.72%

Sovereign Wealth Fund

1.64%

Insurance Company

1.17%

Holding Company

0.20%

Other

32.43%

Institutional Shareholding

Update time: Fri, Feb 21

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

4913

3.83B

67.69%

-85.85M

2024Q4

5153

3.83B

67.74%

-83.25M

2024Q3

5005

3.85B

67.99%

-51.77M

2024Q2

5026

3.83B

67.75%

-120.77M

2024Q1

5032

3.89B

68.71%

-120.38M

2023Q4

5089

3.96B

70.25%

-96.67M

2023Q3

4952

4.00B

70.89%

-71.80M

2023Q2

4962

4.01B

71.16%

-62.34M

2023Q1

4947

4.02B

71.28%

-30.98M

2022Q4

4927

4.00B

71.39%

-30.89M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

515.97M

9.1%

+2.33M

+0.45%

Dec 31, 2024

State Street Global Advisors (US)

290.48M

5.12%

+23.75K

+0.00%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

279.54M

4.93%

+4.28M

+1.55%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

155.45M

2.74%

+25.31M

+19.45%

Dec 31, 2024

Wellington Management Company, LLP

139.99M

2.47%

-23.73M

-14.49%

Dec 31, 2024

Geode Capital Management, L.L.C.

120.58M

2.12%

+2.92M

+2.48%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

87.78M

1.54%

+3.82M

+4.55%

Dec 31, 2024

MFS Investment Management

74.21M

1.3%

+5.44M

+7.92%

Dec 31, 2024

State Farm Insurance Companies

54.50M

0.96%

--

Dec 31, 2024

BlackRock Asset Management Ireland Limited

45.95M

0.81%

+2.00M

+4.55%

Dec 31, 2024

Related ETFs

Update time: 14 hours ago

Name

Proportion

First Trust Morningstar Dividend Leaders Index Fund

7.28%

First Trust NASDAQ Pharmaceuticals ETF

6.22%

Amplify Weight Loss Drug & Treatment ETF

5.32%

NYLI Healthy Hearts ETF

5.04%

iShares U.S. Pharmaceuticals ETF

4.84%

Invesco Pharmaceuticals ETF

4.84%

WBI BullBear Yield 3000 ETF

4.72%

ProShares Smart Materials ETF

4.59%

Schwab U.S. Dividend Equity ETF

4.48%

VanEck Pharmaceutical ETF

4.41%

First Trust Morningstar Dividend Leaders Index Fund

Proportion7.28%

First Trust NASDAQ Pharmaceuticals ETF

Proportion6.22%

Amplify Weight Loss Drug & Treatment ETF

Proportion5.32%

NYLI Healthy Hearts ETF

Proportion5.04%

iShares U.S. Pharmaceuticals ETF

Proportion4.84%

Invesco Pharmaceuticals ETF

Proportion4.84%

WBI BullBear Yield 3000 ETF

Proportion4.72%

ProShares Smart Materials ETF

Proportion4.59%

Schwab U.S. Dividend Equity ETF

Proportion4.48%

VanEck Pharmaceutical ETF

Proportion4.41%

Dividend

A total of 44.91B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Dec 12, 2024

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025

Jan 24, 2025

Mar 07, 2025

Jan 24, 2025

Oct 09, 2024

PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024

Nov 08, 2024

Dec 02, 2024

Nov 08, 2024

Jun 26, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024

Jul 26, 2024

Sep 03, 2024

Jul 26, 2024

Apr 24, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024

May 10, 2024

Jun 14, 2024

May 09, 2024

Dec 14, 2023

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024

Jan 26, 2024

Mar 01, 2024

Jan 25, 2024

Oct 04, 2023

PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023

Nov 10, 2023

Dec 04, 2023

Nov 09, 2023

Jun 22, 2023

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023

Jul 28, 2023

Sep 05, 2023

Jul 27, 2023

Apr 26, 2023

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023

May 12, 2023

Jun 09, 2023

May 11, 2023

Dec 09, 2022

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023

Jan 27, 2023

Mar 03, 2023

Jan 26, 2023

Sep 22, 2022

PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022

Nov 04, 2022

Dec 05, 2022

Nov 03, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

25.940USD

Pfizer Inc

25.940

Overview

Company